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1. Introduction 
This chapter aims at giving a critical overview of the major oxidant and antioxidant changes 
in arterial hypertension, summarizing the experimental and clinical evidence about the 
involvement of oxidative stress in the pathophysiology of hypertension, either as a cause or 
a consequence of this disease. This review also provides a description of the biomarkers 
commonly used to evaluate lipid peroxidation and antioxidant defenses in experimental and 
human hypertension. Finally, we review the strategies (antioxidants, antihypertensive 
drugs) known to prevent or ameliorate oxidative damage, both in animal models of 
hypertension and hypertensive patients. 
2. Pathophysiological role of oxidative stress in arterial hypertension 
2.1. ROS sources and oxidative pathways involved in the pathogenesis of 
hypertension 
In aerobic organisms, the beneficial effects of oxygen come with the price of reactive oxygen 
species (ROS) formation. These highly bioactive and short-lived molecules can interact with 
lipids, proteins and nucleic acids, causing severe molecular damage. However, living 
organisms have evolved specific mechanisms to adapt to the coexistence of ROS. In 
physiological conditions, there is a delicate balance between oxidants and antioxidants that 
not only protects our cells from the detrimental effects of reactive oxygen species (ROS), but 
also allows the existence of redox signaling processes that regulate cellular and organ 
functions. However, the disruption of redox homeostasis, leading to persistent high levels of 
ROS, is potentially pathological [1, 2]. Besides ROS, another group of molecules collectively 
designated as reactive nitrogen species (RNS) also exerts important functions in diverse 
physiological and pathological redox signaling processes. The excess of RNS is often termed 
nitrosative stress [3, 4]. 
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ROS can be classified into two main categories: free radicals [e.g. superoxide (O2.-), hydroxyl 
(HO.), peroxyl (ROO.)], which are highly reactive species due to the presence of one or more 
unpaired electrons, and non-radical oxidants [e.g. singlet oxygen (1O2) hydrogen peroxide 
(H2O2), hypochlorous acid (HOCl)] that have generally more specific reactivity and higher 
stability [3, 5, 6]. RNS include nitric oxide (.NO) and nitrogen dioxide radicals (.NO2 and also 
non radicals such as nitrous acid (HNO2), peroxynitrite (ONOO-), peroxynitrous acid 
(ONOOH) and alkyl peroxynitrites (ROONO) [3]. Among biological ROS and RNS, O2.-, 
H2O2, .NO and ONOO- appear to be especially relevant in neuronal, renal and vascular 
control of blood pressure [3, 7 ,8] (Table 1). Major sources of ROS (and also RNS) within 
these systems include, but are not limited to, NADPH oxidases, xanthine oxidase, 
mitochondrial respiratory chain enzymes, .NO synthases and myeloperoxidase [3, 8, 9].  
 
 Free radicals Non radical oxidants 
ROS 
O2.- 
HO. 
ROO. 
H2O2 
HClO 
RNS .NO ONOO_ 
Table 1. Reactive oxidant species involved in cardiovascular and renal physiology or pathophysiology 
NADPH oxidases (Nox) are enzyme complexes that catalyze the reduction of molecular 
oxygen using NADPH as an electron donor. Generally, the product of the electron transfer 
reaction is O2.- but H2O2 is also rapidly formed from dismutation of Nox-derived O2.- due to the 
presence of superoxide dismutase (SOD) in the cells or by spontaneous reaction. Nox-derived 
ROS have been shown to play a role in host defense and also in diverse signaling processes 
[10]. The Nox family comprises seven members (Nox1-5 and Duox1-2) with distinct tissue 
distribution and functions [10, 11]. So far, only Nox1, Nox2 and Nox4 have been shown to play 
relevant roles in hypertension pathophysiology [5, 8, 10]. These isoforms are localized in major 
sites of blood pressure control. For example, Nox1, Nox2 and Nox4 are expressed in the central 
nervous system where they appear to regulate sympathetic nerve activity [8]. Nox2 and Nox4 
participate in the regulation of renal functions and contribute to end-organ damage associated 
with hypertension [8, 12]. In the vasculature, Nox1 controls smooth muscle cell growth and 
migration, Nox2 contributes to endothelial dysfunction and Nox4 controls vascular smooth 
muscle cell differentiation and improves endothelial-dependent vasodilatation [8, 13, 14]. 
Xanthine oxidoreductase has two inter-convertible forms, xanthine dehydrogenase (XDH) and 
xanthine oxidase (XO), that participate in purines metabolism catalyzing the conversion of 
hypoxanthine to xanthine and xanthine to uric acid [15, 16]. XDH preferentially uses NAD+ as 
an electron acceptor while the oxidase reduces molecular oxygen in a reaction that generates 
O2.- and H2O2 [15, 16]. The XO form predominates in oxidative stress conditions and may 
contribute to endothelium dysfunction due to its localization in the luminal surface of vascular 
endothelium [16, 17]. Besides the production of ROS by XO, both XDH and XO generate uric 
acid which possesses antioxidant properties, such as scavenging of ONOO- and HO., 
prevention of oxidative inactivation of endothelium enzymes and stabilization of Vitamin C 
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[18-22]. On the other hand, uric acid may also have prooxidant and proinflammatory effects 
[23, 24]. Indeed, high systemic levels of uric acid are associated with increased cardiovascular 
disease and poor outcome but it is not clear whether these effects reflect deleterious actions of 
uric acid or the oxidative damage caused by XO-derived ROS [23, 25].  
Mitochondrial respiratory chain enzymes are primary intracellular sources of ROS. More 
than 90% of the total oxygen consumed by aerobic organisms is utilized by mitochondrial 
oxidases which produce ATP in a process coupled to the reduction of cellular oxygen to 
water [26]. About 1-4% of the oxygen used in these reactions is converted to O2.- and H2O2 
which can be largely detrimental to mitochondrial functions if not adequately detoxified [26-
28]. ROS levels in the mitochondria are regulated by the respiratory rate and manganese 
SOD [29]. Hypertensive animals have increased mitochondrial ROS production in the 
vessels, kidney and CNS [30-32]. 
.NO synthases (NOS) constitute a family of enzyme isoforms (neuronal NOS, nNOS; 
inducible NOS, iNOS; endothelial NOS, eNOS) that produce .NO in a reaction that converts 
L-arginine to L-citrulline [28]. However, in conditions of limited bioavailability of the 
cofactor tetrahydrobiopterin, or the substrate L-arginine, these enzymes become unstable 
and reduce molecular oxygen to O2.- instead of .NO production (uncoupled NOS) [28, 29]. 
NOS uncoupling is more often described for eNOS and is triggered by oxidative/nitrosative 
stress [28, 33]. Numerous experimental studies have shown that arterial hypertension is 
associated with eNOS dysregulation and endothelial dysfunction [34, 35]. 
Myeloperoxidase (MPO) is a heme protein secreted by activated neutrophiles and 
monocytes in inflammatory conditions and produces several oxidizing molecules that can 
affect lipids and proteins [28, 36]. MPO uses H2O2 to produce ROS such as HOCl, 
chloramines, tyrosyl radicals and nitrogen dioxides [36, 37]. Although MPO-derived ROS 
have a primary role in microbial killing, they also cause tissue damage in the heart, vessels, 
kidney and brain and appear to contribute to endothelial dysfunction [37, 40]. Figure 1 
illustrates the major sources of ROS and/or RNS generation.  
Of all the putative oxidative pathways involved in the pathogenesis of hypertension, the 
impairment of endothelial-dependent vasorelaxation by O2.- is by far the most studied [41-
44]. In conditions of increased O2.- bioavailability, this ROS rapidly inactivates endothelial-
derived .NO leading to endothelial dysfunction [41]. In addition, O2.- may also modulate 
vascular tone by increasing intracellular Ca2+ concentration in vascular smooth muscle cells 
and endothelial cells [45]. The imbalance between O2.- and .NO also affects the renal 
function, leading to enhanced sodium reabsorption and increased ONOO- formation, which 
contributes to tissue damage [12, 46]. In the CNS, elevated O2.- generation also appears to 
contribute to hypertension by reducing the cardiovascular depressor actions of .NO in the 
rostral ventrolateral medulla [47]. In recent years H2O2 has also emerged as a pivotal 
molecule in the pathophysiology of arterial hypertension [48-50]. Of note, H2O2 seems to be 
even more harmful than O2.- due to its higher life span and diffusibility within and between 
cells [7, 51]. Furthermore, the conversion of O2.- to H2O2 appears to be favored in 
cardiovascular diseases since the expression and activity of SOD is enhanced by 
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inflammatory cytokines in hypertension or in response to the pressor peptide, angiotensin II 
[7]. Several prohypertensive effects have been described for H2O2, such as increased 
vasoconstriction, vascular hypertrophy and hyperplasia, decreased diuresis and natriuresis 
and also increased spinal sympathetic outflow [7, 50, 52-58]. Increasing evidence has also 
shown that H2O2 amplifies oxidative stress by stimulating ROS generation by NADPH 
oxidases, XO and eNOS [7, 51]. In addition, H2O2 also appears to enhance the activation of 
the intrarenal renin-angiotensin system, a major regulator of blood pressure and renal 
function [49]. Altogether, these effects propagate H2O2 generation and prolong the redox 
pathologic signaling involved in blood pressure dysregulation. The oxidative mechanisms 
contributing to hypertension are summarized in Table 2. 
 
Figure 1. Sources of ROS and/or RNS generation - In normal cells, 1–2% of electrons carried by the 
mitochondrial electron transport chain leak from this pathway and pass directly to oxygen generating 
superoxide radical (O2.-) which can be a source of other ROS. O2.- can also be formed by xanthine 
oxidase (XO) which catalyzes the oxidation of hypoxanthine and xanthine. All NOX enzymes utilize 
NADPH as an electron donor and catalyze transfer of electrons to molecular oxygen to generate O2.- 
and/or H2O2. Nitric Oxide synthases (NOS) generate .NO and L-citrulline from arginine and O2. Under 
pathologic conditions of oxidative stress, or when tetrahydrobiopterin (BH4) or L-arginine are deficient, 
NOS enzymes become structurally unstable (uncoupled NOS) resulting in production of O2.- rather than 
.NO. Activated monocytes also secrete a heme enzyme, myeloperoxidase(MPO), that uses H2O2 as a 
substrate to generate products that can oxidize lipids and proteins. One of these oxidants is 
hypochlorous acid (HOCI) which plays a critical role in host defenses against invading bacteria, viruses, 
and tumor cells but may also injure normal tissue. Within cell membranes, ROS can trigger lipid 
peroxidation, a self-propagating chain-reaction that can result in significant tissue damage.  
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Affected organ Oxidative stress consequences 
Major ROS and RNS 
involved 
Vasculature Impaired endothelium-dependent 
vasodilation 
 
Increased vasoconstriction 
 
Increased hypertrophy and hyperplasia
O2.-, .NO, ONOO- 
 
 
O2.-, H2O2 
 
O2.-, H2O2 
Kidney Decreased blood flow 
Increased salt reabsorption 
 
Tissue damage 
O2.-, H2O2 
O2.-, H2O2 
 
HO., HClO, ONOO- 
Brain/Spinal cord Increased sympathetic efferent activity O2.-, H2O2 
Table 2. Putative oxidative pathways leading to arterial hypertension 
2.2. Evidence for redox changes in experimental and human hypertension 
In the last two decades several studies have consistently observed increased oxidative 
stress in experimental and human arterial hypertension. Studies in diverse experimental 
models of hypertension have demonstrated raised prooxidant activity and ROS levels, 
altered antioxidant defenses and increased ROS-mediated damage, both at peripheral and 
central sites of cardiovascular regulation [8, 33, 59]. In human hypertensive patients there 
is also evidence of redox dysfunction. O2.- release from peripheral polymorphonuclear 
leucocytes is higher in hypertensive patients than in normotensive subjects [60]. Plasma 
H2O2 production is also raised in hypertensive patients. Furthermore, among still 
normotensive subjects, those with a family history of hypertension have a higher H2O2 
production [61, 62]. An elevation of several oxidative stress byproducts, such as 
malondialdehyde, 8-isoprostanes, 8-oxo-2’-deoxyguanosine, oxidized low density 
lipoproteins, carbonyl groups and nitrotyrosine has also been observed in plasma or 
serum, urine or blood cells of hypertensive patients [63-66]. Furthermore, both enzymatic 
and non-enzymatic antioxidant defenses appear to be significantly reduced in human 
hypertension [65, 67]. Alterations of redox biomarkers in human hypertension are 
summarized in Table 3. 
 
 Biomarker Evaluated in: Alteration in 
hypertensive 
patients 
References 
ROS/RNS O2.- Peripheral PMN  [60] 
H2O2 Plasma
Lymphocytes 

 
[61, 62] 
[68] 
 NOx Plasma
Urine 

 
[69] 
[70] 
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 Biomarker Evaluated in: Alteration in 
hypertensive 
patients 
References 
Prooxidant 
enzymes 
NADPH oxidase 
activity 
p22phox (Nox subunit) 
mRNA and protein 
expression 
Mononuclear cells
 
Mononuclear cells 

 
 
[71] 
 
[71] 
Oxidative or 
nitrosative stress 
byproducts 
Malondialdehyde 
(MDA)/Thiobarbituric 
acid reactive 
substances (TBARS) 
Plasma 
 
Erythrocytes  
 
Mononuclear cells 
and whole blood 

 
 
 
 
 
[67, 72] 
 
[64, 73, 74]  
 
[65] 
F2-Isoprostane (or 8-
isoprostane or 8-epi-
PGF2) 
Plasma 
 
 
Urine 

 
 
 
[63, 66, 74] 
  
[63, 74, 75] 
8-Oxo-2’-
deoxyguanosine 

 
 
[65] 
 
[76, 77] 
Carbonyl groups Serum  [64] 
Oxidized low density 
lipoproteins 
Plasma  [63, 78]  
 3-Nitrotyrosine Plasma  [66, 79] 
Redox status GSSG/GSH 
 
 
GSH/GSSG 
Mononuclear cells 
and whole blood 
 
Erythrocytes 

 
 
 
[65] 
 
 
[74] 
Antioxidants GSH Mononuclear cells 
and whole blood 
 
Erytrocytes 

 
 
 
[65] 
 
 
[64] 
Uric acid Plasma
Serum 

 
[79] 
[80] 
Vitamin C
(ascorbic acid) 
Plasma
Serum 

 
[67] 
 [81] 
Vitamin E
(-Tocopherol, 
Erytrhocytes  [67] 
Total antioxidant status 
(TAS) 
 
Ferric reducing activity 
of plasma (FRAP) 
Plasma
 
 
Plasma 

 
 
 
[63, 82] 
 
 
[74, 83] 
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 Biomarker Evaluated in: Alteration in 
hypertensive 
patients 
References 
SOD activity
 
Erythrocytes
 
Whole blood and 
mononuclear cells 

 
 
 
[64, 74]  
 
[65] 
Catalase activity Erythrocytes
Whole blood and 
mononuclear cells 
 or 
 
 
[64, 74] 
 
[65] 
Glutathione peroxidase 
activity 
Erythrocytes
Whole blood and 
mononuclear cells 

 
 
[64, 74] 
 
[65] 
Glutathione-S-
transferase activity 
Erythrocytes  [64] 
NOx- nitrites and nitrates; PMN – Polymorphonuclear leucocytes; GSH – reduced glutathione; GSSG- oxidized 
glutathione; 
Table 3. Altered oxidative/nitrosative stress biomarkers in human arterial hypertension 
2.3. Oxidative stress as a cause for arterial hypertension 
Whether oxidant imbalance is a cause or a consequence of high blood pressure remains a 
debatable question. The hypothesis that oxidative stress contributes to arterial hypertension 
is supported by several lines of evidence: (1) the induction of oxidative stress by the 
administration of lead or the glutathione synthesis inhibitor, buthionine sulfoximine, or the 
SOD inhibitor, sodium diethyldithiocarbamate, increases blood pressure in rats [48, 84]; (2) 
the infusion of H2O2 into the renal medulla leads to hypertension [48]; the treatment of 
hypertensive animals with antioxidants or inhibitors of ROS production prevents or 
attenuates hypertension [50, 85-87]; (3) the manipulation of genes related to ROS generation 
or elimination can alter blood pressure [88, 89]; (4) the in vitro exposure of cells and tissues 
to exogenous oxidants reproduces events involved in the pathophysiology of hypertension 
[43]; (5) systemic and tissue redox dysfunction appears to precede the blood pressure 
elevation [90]. 
2.4. Oxidative stress as a consequence of arterial hypertension 
Arterial hypertension is associated with oscillatory shear stress and vascular stretch caused 
by increased vascular pressure. These mechanical forces are known to induce oxidative 
stress and vascular damage [91]. Furthermore, there is evidence that lowering blood 
pressure per se causes reduction of oxidative stress and improvement in endothelial function 
[92]. Several antihypertensive drugs with distinct mechanisms of action have been shown to 
decrease oxidant biomarkers in experimental and human hypertension [93-95]. However, 
there is limited evidence supporting the use of antioxidants to lower blood pressure in 
human hypertensive patients [5, 92]. Nevertheless, the failure of these studies does not 
 Lipid Peroxidation 352 
exclude a role for oxidative stress in human essential hypertension but instead suggests that 
the antioxidant supplementation approach was not the appropriate therapeutic strategy 
[96]. 
3. Biomarkers of redox status in arterial hypertension 
The evaluation of redox status may provide valuable information about the pathogenesis 
and progression of arterial hypertension and related cardiovascular and renal diseases. 
However, the short lifetime of ROS turns their assessment in animal models and humans 
a significant challenge, leading to a growing interest in the development and validation of 
oxidative stress biomarkers. Traditional approaches to evaluate oxidant status have 
frequently relied on indirect measurements of ROS bioavailability (e.g. evaluation of 
prooxidant and antioxidant activity, oxidized products from ROS and the GSH/GSSG ratio) 
as indicators of normal biological processes, pathogenic processes, or pharmacologic 
responses to therapeutic intervention [9, 96-99].  
A biomarker of oxidative stress is classically defined as a biological molecule whose 
chemical structure has been modified by ROS and that can be used to reliably assess 
oxidative stress status in animal models and humans [100]. The ideal biomarker of oxidative 
stress depends on its ability to contribute to an early indication of disease severity and/or its 
progression, as well as to evaluate therapy efficacy. The measurement of redox status 
biomarkers may also help to clarify the pathophysiologic mechanisms mediating oxidative 
injury and may allow the prediction of disease. Ideally, biomarkers of oxidative damage for 
human studies would be evaluated in specimens that can be collected relatively easily, such 
as blood or urine. However, to serve these purposes, an ideal biomarker of oxidative 
damage should fulfill several conditions, such as: a) being a stable product, not susceptible 
to artifactual induction, oxidation, or loss during sample handling, processing, analysis, and 
storage; b) having a well-established relationship with the generation of ROS and/or 
progression of disease; c) allowing direct assessment in a target tissue or being able to 
generate a valid substitute that quantitatively reflects the oxidative modification of the 
target tissue; d) being present at concentrations high enough to be a significant detectable 
product; e) showing high specificity for the reactive species in question and free of 
erroneous factors from dietary intake; f) being noninvasive; g) being measurable by a 
specific, sensitive, reproducible and inexpensive assay; h) being measurable across 
populations; i) being present in concentrations that do not vary widely in the same persons 
under the same conditions at different times [97]. 
3.1. Systemic and tissue antioxidant defenses 
ROS are involved in many biological processes including cell growth, differentiation, 
apoptosis, immunity and defense against micro-organisms [1, 101, 102]. Low or moderate 
concentrations of ROS are beneficial for living organisms. However, high concentrations of 
ROS can cause direct damage of macromolecules such as DNA, proteins, carbohydrates, and 
lipids, or disrupt redox signaling and control pathways, leading to a myriad of human 
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diseases [103]. ROS bioavailability is determined by the balance between their production by 
prooxidant enzymes and their clearance by various antioxidant compounds and enzymes 
[1]. As defined by Halliwell and Gutteridge, an antioxidant is any substance that, at low 
concentration, is able to significantly delay or inhibit the oxidation of an oxidizable substrate 
[104]. Biological antioxidant defenses have evolved to match the diversity of prooxidants 
and several enzymatic and non-enzymatic molecules exist in cells and body fluids to control 
ROS levels within the physiological range [105]. The coordinated action of antioxidants 
results in the interception and deactivation of the damaging species. For example, the 
radical chain events initiated by free radicals can be terminated by the interaction of radicals 
with different non-enzymatic antioxidants [e.g. GSH, ascorbic acid, uric acid, α-tocopherol, 
etc] or prevented by specialized enzymatic defenses such as SOD, catalase and glutathione 
peroxidase (GPx) [105, 106]. The reduction of antioxidants bioavailability disrupts redox 
homeostasis leaving organisms more vulnerable to oxidative damage. Therefore, 
antioxidants may be useful biomarkers for risk stratification and disease prognostication. 
3.2. Enzymatic antioxidants defenses 
All eukaryotic cells possess powerful antioxidant enzymes which are responsible for 
neutralizing ROS.The first line of defense against ROS is achieved by SOD which is active in 
catalyzing the detoxication of O2.-. This radical can be readily converted into H2O2 by SOD 
enzymes present in the cytosol and organelles (Cu,Zn-SOD or SOD-1), mitochondria (Mn-
SOD or SOD-2) and extracellular fluids (EC-SOD or SOD-3) [36, 107, 108]. H2O2 generated in 
this reaction can be further decomposed to water and oxygen. This is achieved primarily by 
catalase in the peroxisomes and also by GPx enzymes in the cytosol and mitochondria [107, 
108]. GPx are selenium-containing enzymes whose activity is dependent on GSH availability 
[108]. Besides neutralizing H2O2, GPx also degrades lipid hydroperoxides to lipid alcohols 
[36]. These reactions lead to the oxidation of GSH to GSSG. Catalase and GPx are 
differentially required for the clearance of high-levels or low-levels of H2O2, respectively 
[36]. Figure 2 illustrates major antioxidant enzymatic pathways.  
In addition to these key antioxidant enzymatic defenses, there are other specialized enzymes 
with direct and/or indirect antioxidant functions. Glutathione reductase (GR) is responsible 
for the replenishment of GSH from GSSG disulphide. Glutathione-S-transferase catalyzes 
the conjugation of GSH with reactive electrophiles and is also involved in the detoxification 
of some carbonyl-, peroxide- and epoxide-containing metabolites produced within the cell 
in oxidative stress conditions [109]. Peroxiredoxins are selenium-independent enzymes that 
decompose H2O2, organic hydroperoxides and peroxynitrite [110]. Thioredoxin (Trx) and 
glutaredoxin (Grx) systems include several enzymes that regulate the thiol-disulphide state 
of proteins and influence their structure and function [110]. Trx isoforms reduce disulphide 
bonds in proteins, especially in peroxiredoxins and Trx reductase regenerates the oxidized 
Trx. Grx protects proteins SH-groups from irreversible oxidation by catalyzing S-
glutathionylation and restores functionally active thiols through catalysis of 
deglutathionylation [110]. Grx enzymes are functionally coupled to GR which reduces the 
GSSG produced in the deglutathionylation reaction [110].  
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Figure 2. Major antioxidant enzyme defenses  
Hypertensive patients have reduced activity and decreased content of antioxidant enzymes, 
including SOD, GPx, and catalase [43]. However, several studies have also described an 
adaptive increase in antioxidant enzyme activities in some experimental models of 
hypertension [50, 111, 112]. The uncoordinated activity of antioxidant enzymes may 
aggravate oxidative stress. For example, the increased dismutation of O2.- by SOD 
significantly increases H2O2 concentration, and may lead to deleterious consequences for the 
tissue in the absence of compensation of catalase and GPx activities [113]. Examples of 
altered antioxidant defenses in human and experimental hypertension are shown in Table 3 
and Table 4, respectively. 
 
Biomarker Evaluated 
in: 
Alteration Hypertension Model Reference 
SOD Brain  expression and activity of 
Mn-SOD 
 
 Cu, Zn-SOD activity 
 
 expression and activity of 
SOD1 and SOD2 
Spontaneously hypertensive rats 
(SHR) 
 
Stroke prone spontaneously 
hypertensive rats (SHRSP) 
 
SHR 
[114]  
 
 
[115] 
 
 
[116] 
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Biomarker Evaluated 
in: 
Alteration Hypertension Model Reference 
Kidney  expression of EC-SOD 
 
 SOD activity 
 
 
 expression of SOD1 and 
SOD3 
SHR 
 
Angiotensin II (Ang II) induced 
hypertension 
 
SHR 
[117] 
 
[49] 
 
 
[118] 
Arteries   SOD activity 
 
 
 SOD activity 
 
 expression and activity of 
Cu, Zn-SOD and Mn-SOD 
Hypertension induced by renin-
angiotensin system (RAS) activation 
 
SHR 
 
 
SHR 
[50] 
 
 
[119, 120] 
 
 
[121] 
Catalase Brain  Catalase expression and 
activity 
 
 Catalase activity 
SHR 
 
 
Renovascular hypertensive rat; SHR 
[116] 
 
 
[122, 123] 
Kidney  Catalase activity 
 
 Catalase expression 
 
 Catalase expression 
SHR; Ang II-induced hypertension; 
 
SHR 
 
SHR 
[49, 122] 
 
 [124] 
 
[125]  
Arteries   Catalase activity 
 
 
 Catalase activity 
Hypertension induced by RAS 
activation 
 
SHR 
[50] 
 
 
[120] 
GPx Brain  GPx activity SHR [122] 
Kidney  GPx activity 
 
 GPx expression 
 
  GPx activity 
Ang II-induced hypertension 
 
SHR 
 
SHR 
[49] 
 
[124, 125] 
  
[122]  
Arteries  GPx activity 
 
 
 GPx activity 
 
 
 GPx expression 
Hypertension induced by RAS 
activation 
 
SHR 
 
 
Salt- sensitive hypertension 
(Ovariectomized female rats) 
[50] 
 
 
[120] 
 
 
[126] 
 
Table 4. Alterations in major antioxidant enzyme defenses in the brain, kidney and arteries in 
experimental models of hypertension 
 Lipid Peroxidation 356 
3.3. Non-enzymatic antioxidants defenses 
Non-enzymatic antioxidants such as GSH, ascorbic acid (vitamin C) and α-tocopherol (vitamin 
E) play an excellent role in protecting the cells from oxidative damage [4]. GSH has a potent 
electron-donating capacity that renders GSH both a potent antioxidant per se and a 
conventional cofactor for enzymatic reactions that require readily available electron pairs. In 
physiological conditions, GSH is present inside the cells mainly in its reduced form and less 
than 10 percent of total GSH exists in the oxidized form, GSSG [127]. Therefore, intracellular 
GSH status can be used as a sensitive marker of the cell health and resistance to toxicity. 
Furthermore, it has been demonstrated that GSH depletion can lead to cell apoptosis [128]. The 
measurements of GSH and GSSG have been considered useful indicators of the status of 
oxidative stress [4, 129]. Vitamins E and C are among the major dietary antioxidants. The 
vitamins have received considerable attention in clinical trials of primary and secondary 
prevention of cardiovascular diseases (CVD) and cancer. Vitamin E is found in lipoproteins, 
cell membranes and extracellular fluids. It terminates lipid peroxidation processes and 
converts O2.-and HO. to less reactive forms [130]. Vitamin C, a water soluble antioxidant, is 
found in high concentrations in the adrenal and pituitary glands, liver, brain, spleen and 
pancreas. It is hydrophilic and can directly scavenge ROS and lipid hydroperoxides. Vitamin C 
can also restore oxidized vitamin E and can spare selenium [131]. Carotenoids, such as -
carotene are lipid soluble antioxidants that function as efficient scavengers of 1O2 but may also 
quench ROO. radicals [108]. Uric acid is a highly abundant aqueous antioxidant, considered to 
be the main contributor for the antioxidant capacity in the plasma [96, 132]. It has the ability to 
quenche HO. and ONOO- and may prevent lipid peroxidation [21, 132]. The scavenging of 
ONOO- by uric acid is significantly increased in the presence of Vitamin C and cysteine which 
regenerate the urate radical formed in these reactions. Uric acid also acts as a chelator of iron in 
extracellular fluids [16]. However, once inside the cells, uric acid appears to exert prooxidant 
effects. It is not clear whether the correlation between the raised plasma levels of uric acid and 
cardiovascular risk are due to increased ROS generation by XO or to the prooxidative effects of 
uric acid itself. Some authors speculate that the increased concentrations of urate might be an 
adaptive mechanism that confers protection from oxidative damage [132]. It is likely that uric 
acid effects have different consequences depending on the surrounding microenvironment 
[21]. Bilirrubin, the end-product of heme catabolism, also appears to function as a chain-
breaking antioxidant [133]. Low circulating bilirrubin levels are considered a risk factor for 
cardiovascular diseases [134]. Plasma albumin, the predominant plasma protein, is also an 
antioxidant due to its sulfhydryl groups and is able to scavenge MPO-derived chlorinated 
reactive species and ROO. radicals [108, 135]. 
The combined antioxidant activities of aqueous- and lipid-antioxidants, including GSH, 
vitamins, uric acid, bilirrubin, albumin, etc, can be evaluated in the plasma and serum by 
several assays that measure the ability of the antioxidants present in the sample to inhibit 
the oxidation of the cation radical ABTS+ [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic 
acid] (Total Antioxidant Status assay), to reduce a ferric-tripyridyltriazine complex (Ferric 
Reducing Ability of Plasma, FRAP assay) or to trap free radicals (Oxygen Radical 
Absorbance Capacity, ORAC assay; Total radical Trapping Parameter, TRAP) [50, 136-138]. 
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The measurement of the overall antioxidant capacity may be more representative of the in 
vivo balance between oxidizing and antioxidant compounds than the evaluation of 
individual antioxidants [139]. Nevertheless, these assays have also some limitations. First, 
they correlate poorly with each other as the various antioxidants react differently in each 
assay. Second, in biological fluids, uric acid appears to account for more than 50% of the 
total antioxidant activity measured in most assays [108]. However, the putative protective 
effect of uric acid is debatable [140, 141]. 
Under conditions of high ROS levels it is expected a decrease of non-enzymatic antioxidants 
defenses in plasma, since the need for neutralization ROS species implies a higher 
consumption of endogenous antioxidants. For example, decreased levels of antioxidant 
vitamins C and E have been demonstrated in newly diagnosed untreated hypertensive 
patients compared with normotensive control subjects [142-144]. 
3.4. Systemic, urinary and tissue markers of lipid peroxidation 
Measuring oxidative stress in biological systems is complex and requires accurate quantification 
of ROS or damaged biomolecules. One method to quantify oxidative stress is to measure lipid 
peroxidation. Lipids that contain unsaturated fatty acids with more than one double bond are 
particularly susceptible to the action of free radicals. The peroxidation of lipids disrupts 
biological membranes and is thereby highly deleterious to its structure and function [145]. A 
large number of by-products are formed during this process and can be measured by different 
assays. Common biomarkers of lipid peroxidation damage include hydroperoxides, which are 
primary products generated in the initial stages of lipid peroxidation, and secondary products 
formed at later lipid peroxidation stages, such as malondialdehyde (MDA) or F2-isoprostanes 
(Table 5) [146, 147] .The lag time required for the exponential generation of lipid peroxidation 
products can also be used to evaluate the susceptibility of lipid molecules to free radical 
damage. Therefore, lipids with higher resistance to oxidative stress exhibit longer lag times than 
those which are easily attacked by free radicals [147].  
3.5. F2-isoprostanes  
F2-isoprostanes are prostaglandin F2α isomers primarily produced by free radical-catalyzed 
peroxidation of the polyunsaturated fatty acid (PUFA), arachidonic acid [97]. Although 
there is also evidence of F2-isoprostane formation by the action of cyclooxygenase, it is 
currently assumed that systemic and urinary F2-isoprostanes are mostly derived from free 
radical-induced lipid peroxidation, independently of cyclooxygenase enzymatic activity. 
Therefore, F2-isoprostanes have been regarded as reliable biomarkers of oxidative stress. 
Furthermore, F2-isoprostanes have been shown to exert potent vasoconstrictor effects on 
animal and human vessels, suggesting a pathogenic role in cardiovascular diseases and 
have been extensively used as markers of lipid peroxidation in human diseases [74, 75,148]. 
Their high stability and presence in measurable concentrations in many biological tissues 
and fluids, under physiological and pathological conditions, has also allowed the 
establishment of reference intervals and the comparison or monitoring of disease states 
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[97,149,150]. Urine specimens are particularly suited for F2-isoprostanes measurements. 
First, the ex vivo formation of F2 isoprostanes is minimized in these samples due to the low 
urinary lipid content, avoiding the need for time-sensitive sample processing [97, 149, 151, 
152]. Second, they provide a noninvasive route for systemic oxidative stress evaluation. 
Although they can also be locally produced in the kidney, many studies have demonstrated 
that urinary F2-isoprostanes are mainly derived from free F2-isoprostanes filtered from the 
circulation [97, 149, 151, 152]. Only hydrolyzed isoprostanes are excreted into the urine 
whereas blood plasma samples contain both free and esterified isoprostanes. Since plasma 
samples have considerable amounts of arachidonic acid, the addition of preservatives, such 
as butylated hydroxytoluene (BHT) and indomethacin, and the storage at -80°C, are 
recommended to avoid degradation and/or ex vivo formation of F2-isoprostanes [97. 
3.6. TBARS 
The free radical attack to PUFAs in cellular membranes leads to the disruption of cell structure 
and function.  MDA, one of the end products of these oxidative reactions, can be detected in 
several biological fluids and tissues and is therefore used as a biomarker of lipid peroxidation 
and oxidative stress [153]. High MDA levels indicate a high rate of lipid peroxidation [154]. 
The reaction of MDA with 2-thiobarbituric acid (TBA) is frequently used to estimate oxidative 
stress [155]. MDA reacts with TBA under conditions of high temperature and acidity 
generating 2-thiobarbituric acid reactive substances (TBARS) that can be measured either 
spectrophotometrically or spectrofluorometrically. However, these products can also be 
formed by sample autooxidation under assay conditions or by cross-reactivity with non-MDA 
substrates such as bile pigments, proteins, carbohydrates and other aldehydes. Therefore, 
TBARS measurements often originate doubts due to their limited specificity as markers of 
lipid peroxidation [156]. Nevertheless, undesirable autooxidation and non-MDA substrates 
reactivity can be minimized by adding BHT during sample preparation. Plasma TBARS 
measurements have been reported to correlate with some clinical features of cardiovascular 
disease, preeclampsia, ischemia/reperfusion, chronic kidney disease and cerebrovascular 
disorders [157-160]. Since the TBARS assay may overestimate MDA, other methods can be 
used to evaluate lipid peroxidation products, such as the lipid hydroperoxide (LPO) test. The 
principle of the LPO test is that in the presence of hemoglobin, lipid hydroperoxides are 
reduced to hydroxyl derivates with the equimolar production of a methylene blue product, 
which can be quantified spectrophotometrically [161]. 
3.7. HNE 
The aldehyde 4-hydroxy-2-nonenal (4-HNE) is one of the most cytotoxic products of free 
radical attack on ω6-PUFA, namely arachidonic and linoleic acids, being able to react with 
diverse biological molecules such as proteins, peptides, phospholipids and nucleic acids. It 
also acts as an important mediator of oxidant-induced signaling, cellular proliferation and 
apoptosis [97, 162]. 4-HNE can be detected in plasma and several biological tissues under 
physiological conditions but its generation is significantly raised in pathological states 
associated with oxidative stress [97, 162-164]. Renovascular hypertensive rats showed 
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increased 4-HNE deposition in the intima of injured  mesenteric arteries, suggesting the 
presence of free radical injury and cytotoxicity induced by 4-HNE [163]. A wide diversity of 
effects have been demonstrated for 4-HNE depending on its concentration. Concentrations 
below 0.1 microM are within the physiological range and appear to induce chemotaxis and 
stimulation of guanylate cyclase and phospholipase C [165]. 4-HNE concentrations between 
1-20 microM inhibit DNA and protein synthesis and stimulate phospholipase A2. Higher 
concentrations (100 microM and above) are cytotoxic and genotoxic leading to cell death 
[165]. Thus, 4-HNE represents a broad indicator of lipid peroxidation. 
3.8. Early stage of lipid peroxidation products 
Lipid hydroperoxides are the primary products of lipid peroxidation and can further react 
to form secondary products including aldehydes such as MDA and 4-HNE [166,167]. 
Therefore, lipid hydroperoxides may be used to evaluate initial stage or acute lipid 
peroxidation while MDA and 4-HNE appear to be more representative of chronic oxidative 
stress. Recent reports described that 13‐hydroperoxyoctadecadienoic acid (13‐HPODE), a 
precursor to 3‐hydroxyoctadecadienoic acid (13‐HODE) is able to react with proteins 
forming adducts by covalently binding to specific amino acid residues. The Hexanoyl‐
Lysine (HEL) adduct results from the oxidative modification of ω6‐PUFAs such as linoleic 
acid, the predominant PUFA in the human diet, and arachidonic acid [168]. HEL may be 
another useful biomarker for detecting and quantifying the earlier stages of lipid 
peroxidation. Monoclonal antibodies and ELISA kits have been developped, and HEL can 
be detected in oxidatively modified LDL, in human atherosclerotic lesions, human urine and 
serum. It has been also reported that HEL is formed in rat muscle during exercise and that 
its formation is inhibited by antioxidants such as flavonoids [169]. 
The lipid peroxidation biomarkers most commonly evaluated in hypertensive patients or 
experimental hypertension are shown in Table 3 and Table 5, respectively. 
 
Lipid peroxidation 
biomarker 
Measured in: Alteration Experimental model of 
hypertension 
References 
MDA Plasma 
 
Aorta 

 
 
SHR 
 
Salt-loaded SHR 
[170]  
 
[94]  
TBARS Plasma 
 
 
Plasma 
 
Plasma, Heart 
 
 
Urine 
 
Aorta, Left Ventricle

 
 
 
 
 
 
 
 
 

Hypertension induced by RAS 
activation 
 
Ang II-induced hypertension 
 
Mineralocorticoid-induced 
hypertension 
 
Salt-sensitive hypertension 
 
Ang II-induced hypertension 
[50] 
 
  
[171]  
 
[172]  
 
 
[173]  
 
[174]  
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Lipid peroxidation 
biomarker 
Measured in: Alteration Experimental model of 
hypertension 
References 
F2-Isoprostanes Plasma 
 
Plasma 
 
 
Urine

 
 
 
 
 
Salt-sensitive hypertension 
 
Glucocorticoid-induced 
hypertension 
 
SHR
[175] 
 
[87]  
 
 
[170, 176]  
4-HNE Mesenteric arteries 
 
Aorta 

 
 
Renovascular hypertension 
 
SHRSP 
[163]  
 
[177]  
4-HNE adducts Blood  SHR [178]  
Table 5. Lipid peroxidation biomarkers in experimental hypertension 
3.9. Other prooxidant biomarkers 
Besides antioxidants and lipid peroxidation parameters, there are other important indexes of 
oxidant status. These include the expression and activity of prooxidant enzymes, ROS 
concentration, byproducts formed by ROS/RNS interaction with DNA (8-hydroxy-2-
deoxyguanosine) or proteins (3-nitrotyrosine, carbonyl groups) and redox-sensitive 
transcription factors such as nuclear factor kappa B (NF-KB). Major sources of cellular ROS 
include Nox enzymes, mitochondrial electron transport enzymes, uncoupled NOS, XO and 
MPO. Table 6 summarizes several prooxidant biomarkers evaluated in experimental models 
of hypertension. 
 
Biomarkers of 
prooxidant status 
Evaluated in: Alteration Hypertension model Reference 
Mitochondrial electron 
transport chain 
enzymes/ 
mitochondrial ROS 
production 
Brain Oxidative impairment 
of mitochondrial 
enzymes 
SHR [30]  
Kidney  mitochondrial ROS 
production 
SHR, Mineralocorticoid 
hypertension 
[179, 180]  
NADPH oxidase 
family enzymes (or 
NOXs) 
Brain  NADPH oxidase 
activity 
Salt-loaded SHRSP [181]  
Kidney   Nox4 expression,  
NADPH oxidase 
activity 
Ang II–induced 
hypertension 
[49]  
Arteries  expression of 
NAD(P)H oxidase 
subunits (p67(phox) 
and gp91(phox)  
 
 Nox1 and Nox4 
expression 
Ang II-induced 
hypertension 
 
 
 
SHRSP 
 
[182]  
 
 
 
 
[183] 
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Biomarkers of 
prooxidant status 
Evaluated in: Alteration Hypertension model Reference 
 NADPH oxidase 
activity  
Ang II-induced 
hypertension; 
Hypertension induced by 
RAS activation 
 
[50, 184-
186]l 
eNOS Arteries
 
 
Arteries 
Uncoupled eNOS/ 
eNOS-derived ROS 
 
 eNOS expression/ 
eNOS activity 
SHR
 
 
SHR 
[34] 
 
 
[35] 
XO Arteries
 
Arteries
XO activity
 
XO expression 
SHR
 
SHR
[187] 
 
[188] 
H2O2 Kidney, Blood 
/urine 
 renal production/
production in plasma 
/ urinary excretion 
Ang II-induced 
hypertension 
[49] 
MPO Arteries
 
Kidney, Heart, 
Brain 
 MPO activity
 
 MPO activity 
SHRSP
 
Renovascular 
hypertension 
[189] 
 
[190] 
GSH/GSSG Kidney
 
Plasma, Heart, 
kidney 
 ratio
 
 ratio 
SHR
 
Salt-sensitive 
hypertension 
[191] 
 
[192] 
3-nitrotyrosine Kidney  expression SHR [193] 
Protein carbonyl 
groups 
Arteries, Heart, 
Kidney 
 
Kidney 
 expression
 
 
 expression 
SHR
 
 
SHR 
[194] 
 
 
[195] 
8-Hydroxy-2-
deoxyguanosine  
(8-OH-dG) 
Arteries, Heart, 
Kidney,  
 expression SHR
 
[194]. 
NF-κB Kidney
 
 
Arteries 
 activation 
 
 
 activation 
SHR; Ang II-induced 
hypertension 
 
Ang II-induced 
hypertension 
[49, 196] 
 
 
[197] 
Table 6. Other Prooxidant status biomarkers in experimental hypertension 
4. Prophylactic and therapeutic strategies to reduce oxidative damage in 
arterial hypertension 
A plethora of studies has demonstrated that hypertension is associated with an imbalance 
between oxidants and antioxidants that leads to altered cell signaling and oxidative damage. 
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Therefore, extensive research has been conducted in order to identify the ROS involved in 
blood pressure dysregulation, as well as the major prooxidant enzymes and antioxidant 
defenses that contribute to the loss of redox homeostasis in cardiovascular and renal 
systems. Furthermore, studies on experimental models of hypertension recognized several 
important neurohumoral stimuli responsible for ROS overproduction and also the main 
targets for ROS-induced dysfunction [8, 43]. Therapeutic interventions to reduce oxidative 
stress in hypertension have mostly relied on the administration of drugs that increase 
antioxidant capacity or inhibit ROS generation. In addition, other strategies aimed at 
reducing the activation of neurohumoral pathways that stimulate ROS production 
(upstream mediators) or at blocking/repairing the downstream targets affected by ROS have 
also been tested [196, 198, 199]. 
4.1. Targeting oxidative stress in experimental hypertension 
The pharmacological modulation of ROS bioavailability in animal models of hypertension 
has been useful to demonstrate a causative role for oxidative stress in the pathophysiology 
of hypertension [43, 50]. However, the blood pressure lowering efficacy of these strategies 
appears to differ when comparing distinct experimental models [48, 50, 85, 200, 201]. This is 
probably because the development of each animal model was based on a particular 
etiological factor presumably responsible for human hypertension, such as high salt intake, 
overactivation of the renin-angiotensin system, genetic factors or renal disease. Since these 
factors may stimulate different redox pathways, the effectiveness of an antioxidant in one 
model does not necessarily translate to other models or to human essential hypertension 
which is known to have a multifactorial nature. Another important observation is that 
treatments with antioxidants or ROS inhibitors are generally more effective in preventing 
rather than reversing the hypertension [49, 50, 87, 202]. Indeed, there are several studies 
demonstrating that ROS activate feed-forward mechanisms that amplify the cardiovascular 
and renal dysfunction [8, 43, 49, 51]. Once triggered, these pathways may be sufficient to 
sustain the deleterious effects of oxidative stress even after ROS blockade or elimination 
[49]. In vivo drug treatments targeting oxidative stress in experimental models of 
hypertension are reviewed below and their effects on blood pressure are summarized in 
Table 7. 
4.1.1. Drugs inhibiting ROS production 
Apocynin is a methoxy-substituted catechol (4-hydroxy-3-methoxy-acetophenone), originally 
extracted from the roots of the tradicional medicinal herb Picrorhiza kurroa which has anti-
inflammatory properties [203]. Several experimental studies have used apocynin for its ability 
to inhibit Nox enzymes. The mechanism of inhibition involves the blockade of translocation of 
cytosolic protein subunits to the membrane which is crucial for the activation of Nox1 and 
Nox2 [204]. Thus, the effect of apocynin is restricted to inducible Nox enzymes that require 
cytosolic activators and it does not seem to affect constitutively active Nox isoforms and their 
putative physiological actions [204]. However, to be an effective Nox inhibitor, apocynin has to 
undergo a peroxidase-mediated oxidation to be converted into the metabolically active 
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diapocynin [205-207]. The activation of apocynin occurs in the presence of MPO and H2O2 
[205, 207]. This fact suggests that apocynin may function only in conditions of high 
inflammatory and prooxidant activity. Apocynin has also been shown to have direct 
antioxidant properties, being able to scavenge H2O2 derived products [205, 207]. However, it 
can also function as a prooxidant in resting cells [203]. Nevertheless, it is possible that when 
administered in conditions of enhanced oxidative stress, the protective effect prevails.  
Gp91ds-tat is a chimeric peptide that specifically inhibits NADPH oxidase by preventing 
the assembly of its subunits. It is constituted by a segment of gp91phox (gp91ds) important 
for the interaction of this membrane subunit with the cytosolic subunit, p47phox, and by a 
tat peptide from the HIV virus, which allows the uptake of the peptide into the cell [208, 
209]. However, since it is a peptide it may have poor oral bioavailability and may induce 
sensitization reactions. Furthermore, the tat segment may have side effects on cellular 
signaling and activity [204, 208]. Thus, it is not suitable for long treatments or to clinical use 
in the treatment of human cardiovascular diseases. Although it was designed to block Nox2, 
it may also inhibit Nox1 given the substantial degree of homology between the two isoforms 
[204]. As for apocynin, Nox4 is not likely to be affected by gp91ds-tat since it is 
constitutively active and does not require the activation of cytosolic subunits [204].  
Allopurinol and its metabolite oxypurinol are hypoxanthine and xanthine analogs, 
respectively, that inhibit XO activity [16]. At low concentrations, allopurinol is a competitive 
inhibitor of XO, while at higher concentrations it behaves as a non-competitive inhibitor 
[16]. XO rapidly metabolizes allopurinol into oxypurinol, a noncompetitive inhibitor of the 
enzyme which has a much higher half-life and is therefore responsible for most of the 
pharmacological effects of allopurinol [16]. In addition, both allopurinol and oxypurinol 
have intrinsic antioxidant properties, being able to scavenge ROS such as O2.-, HO. and 
HClO [210-212]. However, these effects appear to require higher doses than those required 
for XO inhibition [210]. Allopurinol is approved for the treatment of human patients with 
gout or hyperuricemia, but it has also potential therapeutic application in cardiovascular 
diseases. Most common adverse effects are nauseas, diarrheas, hypersensitivity reactions 
and skin rash [16]. 
4.1.2. Antioxidants 
Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) is a membrane-permeable 
nitroxide that catalyzes the conversion of O2.- to H2O2 thus functioning as a SOD mimetic 
[213, 214]. Tempol protects the lipids or proteins from oxidative damage and interacts with 
other antioxidants to promote the reduction of oxidized lipids [214]. The main 
antihypertensive effect of this drug is related to the reduction of the O2.- interaction with .NO 
which improves vasodilation [213, 214]. It also promotes natriuresis by enhancing the 
vasodilation of renal medullary vessels in a .NO independent manner [214]. Indeed, tempol 
has been shown to have sympatholytic actions, being able to inhibit afferent, peripheral and 
central activation of the sympathetic nervous system [214]. These actions are responsible for 
the rapid fall of blood pressure and heart rate after acute intravenous administration of 
tempol [214]. Nevertheless, some studies reported that the formation of H2O2 by tempol can 
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counteract its vasodilator, natriuretic and antihypertensive effects in models of hypertension 
where H2O2 plays a more prominent role than O2.- [48, 50, 53]. The co-administration of 
catalase in these conditions restores the protective action of tempol [48, 50].  
N-acetylcysteine (NAC) is a thiol containing compound. It is the acetylated derivative of the 
aminoacid L-cysteine and a precursor for reduced glutathione (GSH) [215, 216]. It appears to 
have direct antioxidant action since its free thiol can interact with the electrophilic groups of 
ROS [215]. However, this effect does not seem likely to occur in vivo because NAC has poor 
oral bioavailability being rapidly metabolized into GSH, among other metabolites [216]. 
Thus, the main protective action of NAC is probably related to its role as a GSH precursor, 
which then detoxifies reactive species either by enzymatic or non-enzymatic reactions [216]. 
In humans, NAC is approved as a mucolytic agent because it destroys the disulphide 
bridges of mucoproteins [215]. It is also used as an antidote for acetaminophen poisoning 
which dramatically depletes hepatic GSH content causing severe damage [217]. NAC may 
also have potential therapeutical applications in the treatment of heart diseases [218]. 
Polyethylene glycol-catalase is the conjugated form of the enzyme catalase with 
polyethylene glycol (PEG) which enhances the stability in aqueous solution, reduces 
immunogenicity and decreases sensitivity to proteolysis, thus increasing the circulatory 
half-life of catalase [219]. PEG also enhances the catalase association with cells [219]. The 
antioxidant effect of PEG-catalase results from the enzymatic degradation of H2O2 to water.  
Ebselen (2-phenyl-1,2-benzisoselenazol-3[2H]-one) is a lipid-soluble seleno-organic compound 
that mimics glutathione peroxidase activity, being able to react with H2O2 and organic 
hydroperoxides including membrane-bound phospholipid and cholesterylester 
hydroperoxides [220]. It appears to reduce lipid peroxidation initiated by hydroperoxides but 
not free radicals initiators [221]. In addition, ebselen reacts rapidly with ONOO-. The ebselen 
selenoxid product yielded in this reaction is regenerated to ebselen by GSH, which allows its 
reutilization as a defense against ONOO- [222, 223]. Ebselen also directly inhibits 
inflammation-related enzymes such as 5-lipoxygenase, .NO synthases, protein kinase C, 
NADPH oxidase and H+/K+-ATPase by reacting with the SH group, leading to the formation of 
a selenosulphide complex [221]. Some authors have also proposed that the antioxidant and 
anti-inflammatory actions of ebselen are mediated through interactions with the thioredoxin 
(Trx) system [220]. Reduced Trx is important for growth and redox regulation by thiol redox 
control [220]. Ebselen was found to be an excellent substrate for mammalian TrxR and a highly 
efficient oxidant of reduced Trx. It also seems to function as a Trx peroxidase or peroxiredoxin 
mimic, thus contributing to the elimination of H2O2 and lipid hydroperoxides [220]. Ebselen 
has been used in clinical trials for the treatment of patients with acute ischemic stroke or 
delayed neurological deficit after aneurismal subarachnoid hemorrhage [224, 225]. 
Vitamin C (ascorbic acid) is a water soluble antioxidant found in the body as an ascorbate 
anion. It acts as a free radical scavenger [226]. Although this effect requires higher 
concentrations than those achieved in the plasma by oral administration, ascorbate appears 
to concentrate in tissues in much higher levels than those found in the plasma and can act 
effectively as a ROS scavenger [227]. In addition, it reduces membrane lipid peroxidation 
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and regenerates Vitamin E [226]. Recent reports also suggest that Vitamin C can suppress 
NADPH oxidase activity [227].  
Vitamin E is a generic term for a group of compounds including tocopherols and 
tocotrienols. The isoform -tocopherol appears to be the most abundant in vivo [227]. 
Vitamin E terminates the propagation of the free radical chain reaction in lipid membranes 
and inhibits LDL oxidation [226, 227]. Vitamin E can also have non antioxidant actions 
primarily through the regulation of enzymes involved in signal transduction. Enzymes 
inhibited by vitamin E include protein kinases C and B, protein tyrosine kinase, 
lipoxygenases, mitogen activated protein kinases, phospholipase A2 and cyclooxygenase-2. 
In contrast, vitamin E has stimulatory effects on protein tyrosine phosphatase and 
diacylglycerol kinase [228]. Both vitamins C and E have been shown to stimulate the 
activation of NOS activity and increase .NO synthesis in endothelial cells and thus may 
contribute to improved endothelial-dependent vasodilation in hypertension [229]. However, 
although Vitamins C and E are generally considered to be non-toxic, they can undergo 
oxidation and generate pro-oxidant molecules [226]. Nevertheless, it appears that this is 
more likely to occur with Vitamin E, especially in the absence of sufficient Vitamin C to 
regenerate the -tocopherol radical [227, 230, 231]. 
Alpha-lipoic acid (1,2-dithiolane-3-pentanoic acid or thioctic acid) has a wide range of 
effects on cell functions, acting as an antioxidant, a metal chelator and a signaling mediator 
[232]. Both lipoic acid (LA) and its reduced form dihydrolipoic acid (DHLA), may scavenge 
HO. and HClO, although neither species is able to neutralize H2O2 [232]. DHLA also 
regenerates Vitamins C and E and does not become a free radical after reacting with these 
species. Furthermore, LA and DHLA chelate transition metals, thus reducing the metal-
catalyzed free radical damage [232]. LA also contributes to improve antioxidant defenses by 
increasing the intracellular levels of Vitamin C and GSH. Many of LA protective actions 
have been attributed to its interference in cell signaling processes [232]. For example, LA 
effect on GSH appears to be mediated by nuclear factor erythroid 2- related factor 2 (Nrf2), 
an important transcription factor regulating gene transcription through the Antioxidant 
Response Element. LA was also shown to interact with several kinases and protein 
phosphatases [232]. Its interaction with components of the insulin signaling cascade also 
appears to improve glucose disposal in animal models of diabetes and human diabetic 
patients [232]. In addition, LA improves endothelial .NO synthesis and endothelial-
dependent vasodilation and prevents deleterious modifications of thiol groups in Ca2+ 
channels [232]. It has also important anti-inflammatory effects by inhibiting the activation of 
NF-KB, a transcription factor that regulates the expression of proinflammatory genes [232].  
Pyrrolidine dithiocarbamate (PDTC), a low-molecular weight thiol compound, has the 
ability to scavenge oxygen radicals and to chelate metals [233, 234]. It may also act as a 
prooxidant and a thiol group modulator [233]. PDTC has been shown to interfere with the 
activation of several transcription factors, being a potent inhibitor of NF-KB [233, 234]. 
PDTC can also activate other signaling pathways, such as the extracellular signal-regulated 
kinase (ERK), c-Jun N-terminal kinase (JNK) and the transcription factor Heat Shock Factor 
(HSF) [233, 235]. 
 Lipid Peroxidation 366 
5, 6, 7, 8-Tetrahydrobiopterin (BH4) is a key cofactor of NOS [236, 237]. It is involved in the 
formation and stabilization of eNOS and iNOS [236, 238]. In the absence of BH4, NOS can 
become uncoupled and starts producing O2.- instead of .NO [33, 237]. Furthermore, BH4 also 
possesses direct antioxidant activity, being able to scavenge O2.- and HO. [239]. The 
protective effects of BH4 on the development of hypertension appear to be due an increase in 
eNOS activity, a reduction in O2.- production and a decrease in iNOS expression [199].  
 
Drug Antihypertensive effect Lack of antihypertensive effect 
Apocynin Prevented/attenuated mineralocorticoid-induced 
hypertension [86, 240] 
Prevented/reversed glucocorticoid-induced 
hypertension [241] 
Prevented/reversed adrenocorticotropic 
hormone-induced hypertension [242] 
Prevented the development of Ang II-induced 
hypertension in mice [186] 
Prevented the development of renovascular 
hypertension [243] 
Prevented the development of hypertension 
induced by RAS activation [50] 
Reduced blood pressure in borderline and 
spontaneous hypertension [244] 
Attenuated salt-sensitive hypertension [245] 
Normalized blood pressure in a model of 
hypertension induced by disruption of dopamine 
D2 receptor [246] 
Failed to prevent the hypertension 
induced by chronic infusion of 
endothelin-1 [200] 
 
Failed to prevent hypertension in 
transgenic mice overexpressing renin 
or angiotensinogen [247, 248]  
 
Failed to prevent Ang II-induced 
hypertension in rats [249, 250] 
Gp91ds-tat Attenuated the blood pressure rise induced by 
Ang II in mice [209] 
Failed to attenuate salt-sensitive 
hypertension [251] 
Allopurinol Attenuated salt-sensitive hypertension [252] 
 
 
Prevented glucocorticoid-induced hypertension 
[253]  
Failed to prevent or attenuate 
mineralocorticoid-induced 
hypertension [254] 
Failed to prevent glucocorticoid-
induced hypertension [255] 
Failed to prevent or attenuate 
adrenocorticotropic-induced 
hypertension [242] 
Failed to prevent the development of 
hypertension induced by the blockade 
of nitric oxide synthesis [256] 
Failed to prevent the progression of 
hypertension in young SHR [257] 
Oxypurinol Reduced blood pressure in SHR [258]  
Tempol Attenuated hypertension in SHR [201] 
Prevented the progression of hypertension in salt-
loaded SHRSP [259] 
Attenuated mineralocorticoid-induced 
hypertension [260] 
Failed to prevent Ang II-induced 
hypertension [264] 
Failed to attenuate hypertension 
induced by inhibition of superoxide 
dismutase [48] 
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Drug Antihypertensive effect Lack of antihypertensive effect 
Prevented/attenuated glucocorticoid-induced 
hypertension [87] 
Attenuated salt-sensitive hypertension [261] 
Prevented the development of renovascular 
hypertension [243] 
Attenuated high-volume hypertension [262] 
Attenuated hypertension induced by NO 
inhibition [112] 
Partially prevented/reversed adrenocorticotropic 
hormone-induced hypertension [263] 
Failed to prevent hypertension 
induced by RAS activation [50] 
 
NAC Attenuated hypertension in young SHR [265] 
 
Prevented the development of glucocorticoid-
induced hypertension [202] 
 
Prevented the development of 
adrenocorticotropic hormone-induced 
hypertension [266] 
 
Markedly reduced salt-sensitive hypertension [267]
 
Prevented/ attenuated hypertension induced by 
nitric oxide synthesis inhibition [268] 
Failed to reduce blood pressure in 
adult SHR [265] 
Failed to attenuate glucorticoid-
induced hypertension [202] 
 
Failed to reverse adrenocorticotropic-
induced hypertension [266] 
 
 
Failed to prevent the development of 
hypertension induced by the blockade 
of nitric oxide synthesis [256] 
PEG-
catalase 
Prevented the development of hypertension 
induced by RAS activation [50] 
Transiently decreased blood pressure in Ang II-
hypertensive rats [49] 
Reduced blood pressure in high-volume 
hypertension in mice [269] 
Lacked a sustained antihypertensive 
effect in Ang II-induced hypertension 
[49] 
Ebselen Attenuated the blood pressure rise induced by 
Ang II in mice overexpressing p22phox in 
vascular smooth muscle and in littermate control 
mice [270] 
Failed to prevent the development of 
hypertension induced by the blockade 
of nitric oxide synthesis [256] 
Vitamin C Prevented the progression of hypertension 
induced by salt administration in SHRSP and in 
SHR [229, 271]  
Attenuated salt-induced hypertension [272, 273] 
Failed to prevent adrenocorticotropic 
hormone-induced hypertension [274]  
Vitamin E Prevented the progression of hypertension 
induced by salt administration in SHRSP [229] 
Attenuated hypertension in young SHRSP [275] 
Attenuated salt-induced hypertension [273] 
Failed to prevent adrenocorticotropic 
hormone-induced hypertension [274] 
 
Lipoic acid Reduced blood pressure in SHR [276] 
Prevented fructose-induced hypertension [277] 
Prevented/attenuated salt-induced hypertension 
[278] 
Prevented mineralocorticoid-induced 
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Drug Antihypertensive effect Lack of antihypertensive effect 
hypertension [279] 
PDTC Perinatal administration ameliorated 
hypertension in SHR offsprings [280] 
Prevented /Reduced hypertension in SHR [32, 
196] 
Attenuated mineralocorticoid-induced 
hypertension [260] 
 
BH4 Suppressed the development of hypertension in 
SHR [199] 
Reduced hypertension in SHR [281] 
Failed to attenuate hypertension in 
castrated SHR [281] 
Failed to prevent the development of 
adrenocorticotropic hormone in rat 
[282] 
Table 7. Effect of chronic treatment with antioxidants or inhibitors of ROS production on blood 
pressure 
4.2. Antioxidant approaches in human hypertension 
Although there is considerable evidence of oxidative stress involvement in the 
pathophysiology of hypertension, the attempts to demonstrate benefits from antioxidant 
therapy in human cardiovascular diseases have been very disappointing [5, 96, 283]. Most of 
the large trials regarding the effects of diet supplementation with Vitamin C, Vitamin E and 
-carotene failed to show significant improvements in blood pressure and other 
cardiovascular endpoints [5, 283]. Furthermore, some of them also led to the conclusion that 
antioxidant treatment with Vitamin E or -carotene may even be harmful [283-285]. In 
contrast, smaller clinical trials have provided some evidence of antioxidant treatment 
advantages. For example, some studies showed that systemic Vitamin C levels inversely 
correlates with blood pressure and that Vitamin C supplementation effectively attenuates 
hypertension [142, 286]. Vitamin E and lipoic acid have also been shown to improve 
vascular function, though there is not consistent evidence of a blood pressure lowering 
effect of these agents in human patients [5, 287, 288]. Nevertheless, it has been demonstrated 
that a high consumption of dietary fruits and vegetables increases plasma antioxidant 
capacity and reduces blood pressure [289, 290]. Thus, it appears that a diet rich in fruits and 
vegetables is a better strategy than antioxidant supplementation to improve antioxidant 
status and cardiovascular health [5]. Overall, the clinical trials with antioxidant supplements 
have been very unsatisfactory and are in disagreement with the findings obtained in 
experimental hypertension studies. There are some possible justifications for the 
disappointing outcomes of these trials. First, the type of the drug used as well as the dose 
and duration of the therapy might not be adequate [5, 291, 292]. Most trials followed an 
antioxidant strategy based in the administration of ROS scavengers such as Vitamins C and 
E. However, these drugs do not neutralize H2O2 which has been shown to play a relevant 
role in the pathophysiology of hypertension and other cardiovascular diseases [5, 7, 48-50]. 
Furthermore, it is known that human blood and tissues have plenty antioxidants and that 
several stimuli induce an adaptive increase of enzymatic antioxidant defenses which can 
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mask the benefits of exogenously administered antioxidants [293]. In addition, the 
antioxidant doses used in most of the experimental studies have been much higher than 
those tested in human patients [291]. So, there is the possibility that in humans the 
antioxidants did not achieve effective concentrations to neutralize ROS. Furthermore, it is 
not known if orally administered antioxidants can reach the precise sites of increased ROS 
production as oxidative stress is heterogeneously distributed throughout the organs, tissues 
and cellular compartments [5, 96, 291]. Indeed, the unspecific scavenging of ROS may even 
interfere with many important physiological functions in a deleterious manner [29, 96]. 
Another important limitation of most antioxidants tested is that they can exert themselves 
prooxidant effects in the absence of a coordinated antioxidant response [5, 96]. For example, 
Vitamin E needs to be regenerated by Vitamin C otherwise it may cause oxidative damage 
[231]. 
There are also drawbacks in clinical trials design. In large trials of antioxidant 
supplementation, patients have not been recruited accordingly to their redox status [5, 294]. 
It is unlikely that a beneficial effect of antioxidant therapy would be observed in patients 
without previous evidence of increased oxidative stress. Another important consideration is 
that these clinical trials often have heterogeneous populations in terms of the etiology of 
cardiovascular disease [295]. Indeed, most studies have indiscriminately enrolled any 
patient at cardiovascular risk [294]. This is in obvious contrast to the homogeneous 
populations analyzed in experimental studies. Furthermore, some of the patients may be at 
an advanced stage of disease exhibiting irreversible damage insusceptible to antioxidant 
interventions [5, 29]. It should also be highlighted that many patients enrolled in these 
studies were already being treated with drugs such as aspirin, lipid-lowering agents and 
some antihypertensive drugs which can themselves interfere with oxidant status and mask 
the effects of additional therapy with antioxidants [5, 92, 296, 297].  
So far, most interventions aimed at reducing oxidative stress in human hypertension have 
relied on antioxidant supplementation. However, it is possible that a strategy based on the 
inhibition of ROS production is more effective than the antioxidant interventions [5, 96]. The 
disruption of cardiovascular redox status is most likely triggered by an increase in 
prooxidant activity rather than a reduction in antioxidant defenses. Indeed, many 
neurohumoral or ambiental prohypertensive stimuli (angiotensin II, aldosterone, high-salt 
intake) are known to upregulate the expression and activity of prooxidant enzymes [5, 8, 
43]. Nevertheless, there are already some studies that investigated the cardiovascular effects 
of prooxidant enzyme inhibition. Patients treated with allopurinol showed improvements in 
vascular function [298, 299]. However, a blood pressure lowering effect of this XO inhibitor 
has been shown only in newly diagnosed hypertensive adolescents and in hyperuricemic 
patients with normal renal function [300, 301]. Furthermore, the combination of allopurinol 
with antihypertensive drugs did not provide additional benefits on blood pressure [299]. 
This is probably because XO is not a major contributor to the development of hypertension, 
even though its activity may be increased in pathophysiological conditions [5]. Indeed, 
compelling evidence indicates that NADPH oxidases are the main contributors to ROS 
overproduction in cardiovascular and renal diseases [5, 8, 302]. Moreover, Nox-derived ROS 
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are known to amplify redox dysfunction by inducing the activation of other prooxidant 
enzymes, such as XO, mitochondrial enzymes and NOS synthases [7, 51]. Since many 
antihypertensive drugs block upstream activators of Nox enzymes, it is not surprising that 
the inhibition of XO by allopurinol does not improve blood pressure control in patients 
already treated with antihypertensive drugs. To date, no Nox inhibitors have been tested in 
clinical trials although some specific Nox inhibitors have already been developed and 
patented [96, 296]. Future strategies to demonstrate the benefits of oxidative stress reduction 
in cardiovascular diseases should include the testing of specific Nox inhibitors in human 
patients. Moreover, the development of reliable oxidative stress biomarkers for risk 
stratification and monitoring of therapy is also highly desirable [96, 296]. Table 8 
summarizes the possible reasons for the failure of antioxidants in clinical trials.  
 
Limitations related to the drug treatment Limitations related to the clinical trials design 
Inadequate dose or duration of therapy 
Lack of effect on non-radical oxidants such as H2O2 
Lack of effect on prooxidant activity 
Inaccessibility of ROS scavengers to intracellular sites 
of increased ROS production 
Some antioxidants may themselves become 
prooxidants in the absence of a coordinated 
antioxidant response 
Unspecific scavenging of ROS may disrupt 
physiological functions 
Lack of previous evidence of increased redox 
dysfunction in patients analyzed 
Heterogeneous populations in terms of the 
etiology of cardiovascular disease 
Some patients may be at an advanced stage of 
disease exhibiting irreversible damage 
Patients treated simultaneously with drugs that 
interfere with oxidant status (aspirin, lipid 
lowering agents, antihypertensive drugs) 
Lack of validated oxidative stress biomarkers 
for risk stratification and monitoring of therapy 
Table 8. Possible reasons for the failure of clinical trials with antioxidants in cardiovascular diseases 
4.3. Antihypertensive treatments with direct and indirect antioxidant effects 
It is known that first-line antihypertensive drugs such as angiotensin II receptor blockers 
(ARB) and angiotensin converting enzyme inhibitors (ACEi) can reduce oxidative stress due 
to their inhibitory effect on angiotensin II, which is a major stimulus for the activation or 
upregulation of Nox enzymes [5, 296]. ROS such as O2.- and H2O2 are widely recognized as 
important downstream mediators of Ang II physiological and pathological effects [303]. 
Nevertheless, some of these antihypertensive drugs also possess antioxidant effects 
independently of RAS inhibition. For example, captoptil, a thiol-containing ACEi, is a ROS 
scavenger and a metal chelator [304]. The ARBs candesartan and olmesartan also exhibit 
antioxidant effects independent of AT1 receptor blockade or blood pressure control [305-
307]. In addition, other agents belonging to the beta-blocker or calcium channel blocker drug 
classes have also been shown to exert antioxidant effects unrelated to their blood pressure 
lowering action. The beta-blockers carvedilol and nebivolol appear to possess ROS 
scavenging properties as well as inhibitory effects on ROS production, such as the inhibition 
of Nox activation [308, 309]. In addition, nebivolol also increases .NO release from the 
endothelium, thus attenuating oxidative stress effects on endothelium-dependent 
vasodilation [309, 310]. The calcium channel blocker lacidipine has also been demonstrated 
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to have a potent antioxidant activity and to reduce the intracellular production of ROS 
induced by oxidized LDL [311, 312]. Therefore, even though convincing evidence is lacking 
regarding a clinical therapeutic effect of antioxidants, there is extensive data showing that 
currently approved antihypertensive treatments have the ability to modify oxidative stress 
status. 
5. Conclusions 
Extensive experimental evidence has shown that unbalanced ROS and/or RNS production 
can disturb several physiological functions, leading to the genesis and progression of 
arterial hypertension. Many studies have observed marked alterations in direct and indirect 
oxidative stress biomarkers, such as lipid peroxidation products, prooxidant enzymes and 
antioxidant defenses. However, most clinical trials with antioxidants have failed to 
demonstrate a protective effect on blood pressure and cardiovascular function. This does 
not necessarily exclude a role for oxidative stress in human cardiovascular diseases but 
instead suggests that other approaches should be addopted to recover redox homeostasis. 
The inhibition of Nox enzymes appears to be a promising strategy as these enzymes are 
major sources of ROS overproduction at cardiovascular and renal sites of blood pressure 
control. Indeed, several drugs already in use for the treatment of hypertension (e.g. ARBs, 
ACEi, the -blocker nebivolol) or dyslipidemia (statins) are known to reduce the activation 
of Nox enzymes. In addition, there is an urgent need to implement universally validated 
approaches to evaluate oxidative status in human patients. These should cover a broader 
range of redox biomarkers and would add valuable information for risk stratification and 
therapeutic monitoring in human patients.  
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